

# Jee-Fu Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3713557/publications.pdf>

Version: 2024-02-01

344  
papers

8,186  
citations

53660

45  
h-index

76769

74  
g-index

348  
all docs

348  
docs citations

348  
times ranked

7868  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 960-969.e1.	2.4	12
2	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	2.4	14
3	Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1273-1282.	0.8	6
4	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Liver International</i> , 2022, 42, 59-68.	1.9	10
5	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 157-164.	0.8	1
6	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
7	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). <i>Hepatology International</i> , 2022, 16, 59-67.	1.9	5
8	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. <i>Cancer Medicine</i> , 2022, 11, 104-116.	1.3	7
9	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	1.4	6
10	Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1767-1772.	0.8	7
11	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. <i>World Journal of Gastroenterology</i> , 2022, 28, 263-274.	1.4	10
12	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	0.8	2
13	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	1.5	2
14	Itemization difference of patient-reported outcome in patients with chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0264348.	1.1	2
15	A Pilot First-in-Human Study of Embrace, a Polyethylene Glycol-Based Liquid Embolic Agent, in the Embolization of Malignant and Benign Hypervascular Tumors. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 660-667.	0.2	6
16	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	1.8	13
17	Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. <i>Cancers</i> , 2022, 14, 2023.	1.7	3
18	The compound annual growth rate of the fibrosis index in chronic hepatitis B patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
19	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukan, a hyperendemic area of southern Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	2
20	Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. <i>PLoS ONE</i> , 2022, 17, e0268180.	1.1	2
21	Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, , .	1.5	2
22	Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
23	High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues. <i>Journal of Infection</i> , 2022, 85, e94-e95.	1.7	0
24	The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1901-1910.	1.4	2
25	Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 294-302.	1.9	51
26	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 145-153.	0.8	8
27	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28
28	Effects of Cirrhosis and Diagnosis Scenario in Metabolicâ€Associated Fatty Liver Diseaseâ€Related Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021, 5, 122-132.	2.0	19
29	Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 427-435.	1.4	6
30	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 303-310.	0.8	8
31	Exosomeâ€derived differentiation antagonizing nonâ€protein coding RNA with risk of hepatitis C virusâ€related hepatocellular carcinoma recurrence. <i>Liver International</i> , 2021, 41, 956-968.	1.9	17
32	Realâ€world effectiveness of directâ€acting antiviral agents for chronic hepatitis C patients with genotypeâ€2 infection after completed treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 334-345.	0.8	3
33	Coagulationâ€related inflammatory pseudotumor of liver. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 528-530.	0.8	0
34	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 186-196.	4.5	9
35	The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. <i>PLoS ONE</i> , 2021, 16, e0246376.	1.1	1
36	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021, 16, e0245479.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa-Like Group. <i>Journal of Viral Hepatitis</i> , 2021, 28, 719-727.	1.0	5
38	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 255-260.	0.6	6
39	Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 616-623.	0.8	8
40	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	1.9	29
41	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	1.4	3
42	Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. <i>BMJ Open</i> , 2021, 11, e042861.	0.8	10
43	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2261-2269.	1.4	2
44	Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 313-328.	4.5	8
45	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. <i>Scientific Reports</i> , 2021, 11, 8554.	1.6	11
46	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	1.6	17
47	Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 946-956.	1.9	8
48	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	1.4	10
49	The association between hepatitis C virus infection and renal function. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 757-765.	0.6	5
50	Genetic polymorphisms of regulatory T cell-related genes modulate systemic inflammation induced by viral hepatitis. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 1000-1009.	0.8	1
51	Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. <i>Cancers</i> , 2021, 13, 3455.	1.7	11
52	Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. <i>PLoS ONE</i> , 2021, 16, e0254028.	1.1	6
53	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3239-3246.	1.4	0
54	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. <i>Hepatology International</i> , 2021, 15, 1136-1147.	1.9	23

#	ARTICLE	IF	CITATIONS
55	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	1.9	4
56	The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan. <i>Pathogens</i> , 2021, 10, 1227.	1.2	0
57	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 136-143.	4.5	32
58	Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). <i>Gut</i> , 2021, 70, 2349-2358.	6.1	25
59	The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. <i>Biomedicines</i> , 2021, 9, 1491.	1.4	14
60	The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interleukin-8 Expression. <i>Biomedicines</i> , 2021, 9, 1446.	1.4	3
61	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021, 11, 23473.	1.6	8
62	Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 89-96.	0.8	29
63	Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 151-156.	1.4	6
64	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 473-481.	1.4	7
65	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2120-2129.	1.1	13
66	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	2.9	30
67	Letter to the editor: Successful eradication of HCV by short-course DAAs in HCV-Positive donor to HCV-Negative recipient during Haplo-HSCT. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1717-1718.	0.8	0
68	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4945.	1.8	9
69	Cure or curd: Modification of lipid profiles and cardiovascular events after hepatitis C virus eradication. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 920-928.	0.8	20
70	Editorial: <i>PNPLA3</i> genotype and liver diseases—more than non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 390-391.	1.9	1
71	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.2	19
72	Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa272.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa397.	0.4	3
74	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	1.9	38
75	Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: Some issues. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1508-1508.	1.0	0
76	Review of the present features and the infection control challenges of COVID-19 pandemic in dialysis facilities. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 393-398.	0.8	5
77	Modelling NAFLD disease burden in four Asian regions—2019–2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	1.9	92
78	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 460-466.	0.8	3
79	Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1430-1432.	1.9	0
80	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020, 73, 62-71.	1.8	60
81	Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter. <i>Hepatology</i> , 2020, 72, 781-781.	3.6	2
82	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 750-756.	0.8	2
83	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	1.6	4
84	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1886-1892.	1.4	8
85	Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3732.	1.8	14
86	Proteomic screening of saturated fatty acid-induced hepatocytes-derived exosomes. <i>Journal of Clinical Oncology</i> , 2020, 38, e13568-e13568.	0.8	0
87	Circulating exosome DANCR correlated to the recurrence of hepatitis C virus-related hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, e13688-e13688.	0.8	1
88	Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000543.	1.1	3
89	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242601.	1.1	5
90	DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	2.4	0

#	ARTICLE	IF	CITATIONS
91	Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 249-255.	1.4	10
92	THU-195-An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution. <i>Journal of Hepatology</i> , 2019, 70, e248-e249.	1.8	0
93	<i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. <i>PLoS ONE</i> , 2019, 14, e0220663.	1.1	15
94	The acceptability of serum sample storage for hepatitis C viral load analysis in chronic hepatitis C patients. <i>Advances in Digestive Medicine</i> , 2019, 6, 58-61.	0.1	0
95	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 624-632.	0.8	8
96	FRI-234-Viral interference between dengue virus and hepatitis C virus infections. <i>Journal of Hepatology</i> , 2019, 70, e497-e498.	1.8	0
97	Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 779-785.	1.5	21
98	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	1.9	27
99	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. <i>BMJ Open</i> , 2019, 9, e026703.	0.8	17
100	Integrated care for methadone maintenance patients with hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 501-507.	0.8	5
101	Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection. <i>Cancer Medicine</i> , 2019, 8, 3453-3463.	1.3	19
102	Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. <i>Hepatology Communications</i> , 2019, 3, 493-503.	2.0	22
103	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE) <i>Tj ETQq1 1 0,784314 rgBT /Over Infectious Diseases</i> . 2019, 220, 557-566.	1.9	15
104	Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 277-281.	0.6	5
105	Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 224-229.	0.8	6
106	Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 99-104.	0.6	12
107	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	0.8	11
108	Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1224-1233.	1.9	15

#	ARTICLE	IF	CITATIONS
109	Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. American Journal of Medicine, 2019, 132, e41-e42.	0.6	0
110	Circulating exosomes of long non-coding RNA DANCR correlated to prognosis of Hepatitis C virus-related hepatocellular carcinoma. FASEB Journal, 2019, 33, 662.69.	0.2	0
111	Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. Medicine (United States), 2018, 97, e9782.	0.4	2
112	The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. Journal of the Formosan Medical Association, 2018, 117, 14-23.	0.8	6
113	Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. Journal of the Formosan Medical Association, 2018, 117, 54-62.	0.8	3
114	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. Journal of the Formosan Medical Association, 2018, 117, 497-504.	0.8	4
115	Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association, 2018, 117, 518-526.	0.8	15
116	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1108-1114.	1.4	6
117	More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver International, 2018, 38, 895-902.	1.9	27
118	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. Liver International, 2018, 38, 503-514.	1.9	61
119	Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. Journal of the Chinese Medical Association, 2018, 81, 155-163.	0.6	42
120	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. Hepatology International, 2018, 12, 544-551.	1.9	14
121	Association of hyperuricemia with disease severity in chronic hepatitis C patients. PLoS ONE, 2018, 13, e0207043.	1.1	13
122	Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?. Expert Review of Anti-Infective Therapy, 2018, 16, 907-912.	2.0	11
123	The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. Oncotarget, 2018, 9, 21313-21321.	0.8	10
124	Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. Scientific Reports, 2018, 8, 15821.	1.6	6
125	Toll-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Scientific Reports, 2018, 8, 15058.	1.6	5
126	Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. PLoS ONE, 2018, 13, e0202650.	1.1	15



#	ARTICLE	IF	CITATIONS
127	Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 44-54.	1.9	34
128	Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e166.	1.3	20
129	Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1897-1903.	1.4	6
130	A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 670-675.	0.6	3
131	The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. <i>Oncotarget</i> , 2018, 9, 11291-11302.	0.8	19
132	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. <i>Oncotarget</i> , 2018, 9, 12240-12249.	0.8	5
133	A real-world impact of cost-effectiveness of pegylated interferon/ribavirin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 44-49.	0.8	11
134	Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 686-692.	1.0	15
135	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. <i>EBioMedicine</i> , 2017, 15, 81-89.	2.7	30
136	25-Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy. <i>Hepatology Research</i> , 2017, 47, 1383-1389.	1.8	16
137	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1754-1762.	1.4	59
138	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	1.6	16
139	Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 284-289.	0.8	2
140	Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. <i>Medicine (United States)</i> , 2017, 96, e6984.	0.4	4
141	The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 567-571.	0.8	25
142	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein expression predicts disease severity in chronic hepatitis C patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 394-399.	0.8	9
143	Interactive effects between <i>Lymphotoxin Î±</i> +252 polymorphism and habits of substance use on risk of hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 334-338.	0.8	2
144	Significantly Lower Rates of Cirrhosis and Lower Long-Term Survival in Cryptogenic Hepatocellular Carcinoma (HCC) Compared to Viral Etiologies: Results of a Multi-Center International Cohort. <i>Gastroenterology</i> , 2017, 152, S1071.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Independent and additive interaction between polymorphisms of <i>tumor necrosis factor Î±</i> <sup>308</sup> and <i>lymphotoxin Î±</i> <sup>+252</sup> on risk of hepatocellular carcinoma related to hepatitis B. Kaohsiung Journal of Medical Sciences, 2017, 33, 453-457.	0.8	3
146	Antiviral Therapy is Under-Utilized but Associated with Improved Survival Across Tumor and Liver Disease Stages and Cancer Therapies in HBV-Related Hepatocellular Carcinoma (HCC): Results of a Multicenter United States Asia Cohort of 2307 Patients. Gastroenterology, 2017, 152, S1070-S1071.	0.6	0
147	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. Clinical Cancer Research, 2017, 23, 1690-1697.	3.2	32
148	Disease severity and erythropoiesis in chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 864-869.	1.4	4
149	Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. PLoS ONE, 2017, 12, e0174394.	1.1	11
150	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS ONE, 2017, 12, e0178883.	1.1	18
151	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0184878.	1.1	5
152	The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities. PLoS ONE, 2017, 12, e0164281.	1.1	7
153	Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. PLoS ONE, 2017, 12, e0183851.	1.1	16
154	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget, 2017, 8, 43925-43933.	0.8	12
155	Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. Oncotarget, 2017, 8, 32618-32625.	0.8	6
156	The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma. Oncotarget, 2017, 8, 91902-91913.	0.8	14
157	Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients. Medicine (United States), 2016, 95, e3120.	0.4	26
158	Long-term efficacy of Peg-interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 835-841.	1.4	8
159	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Scientific Reports, 2016, 6, 22995.	1.6	7
160	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	7.7	172
161	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology International, 2016, 10, 681-701.	1.9	75
162	Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan. Kaohsiung Journal of Medical Sciences, 2016, 32, 96-102.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 526-530.	0.8	12
164	The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 362-366.	0.8	22
165	Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 559-566.	0.8	2
166	Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. <i>Medicine (United States)</i> , 2016, 95, e4157.	0.4	29
167	Mo1507 Cirrhosis Is Associated With More Advanced Tumor Stage, Decreased Treatment Eligibility, and Lower Survival in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC): Results of a Multicenter International Cohort Study. <i>Gastroenterology</i> , 2016, 150, S1134-S1135.	0.6	0
168	MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication. <i>Journal of Molecular Medicine</i> , 2016, 94, 311-320.	1.7	12
169	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. <i>Oncotarget</i> , 2016, 7, 61325-61335.	0.8	7
170	Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin. <i>Medicine (United States)</i> , 2015, 94, e1837.	0.4	12
171	Amiodarone as an autophagy promoter reduces liver injury and enhances liver regeneration and survival in mice after partial hepatectomy. <i>Scientific Reports</i> , 2015, 5, 15807.	1.6	51
172	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	1.6	7
173	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	1.6	8
174	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1768-1774.	1.4	14
175	Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. <i>Medicine (United States)</i> , 2015, 94, e690.	0.4	94
176	Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. <i>PLoS ONE</i> , 2015, 10, e0139796.	1.1	16
177	Serological investigation to identify risk factors for post-flood infectious diseases: a longitudinal survey among people displaced by Typhoon Morakot in Taiwan. <i>BMJ Open</i> , 2015, 5, e007008-e007008.	0.8	10
178	Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 77-82.	0.8	11
179	Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 26-33.	0.8	2
180	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	6.1	39

#	ARTICLE	IF	CITATIONS
181	Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 62, 512-518.	1.8	30
182	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. <i>Scientific Reports</i> , 2015, 5, 11901.	1.6	9
183	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 271-277.	0.8	3
184	Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 879-884.	1.4	55
185	Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0122259.	1.1	16
186	Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection. <i>PLoS ONE</i> , 2014, 9, e94791.	1.1	44
187	Abbott RealTime HBV Assay Is More Sensitive in Detection of Low Viral Load and Little Impacted by Drug Resistant Mutation in Chronic Hepatitis B Patients under Nucleot(s)ide Analogues Therapy. <i>PLoS ONE</i> , 2014, 9, e101790.	1.1	10
188	Discrepancy between Serological and Virological Analysis of Viral Hepatitis in Hemodialysis Patients. <i>International Journal of Medical Sciences</i> , 2014, 11, 436-441.	1.1	16
189	Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1012-1018.	1.4	8
190	Cirrhosis as a Risk Factor for Tuberculosis Infection—A Nationwide Longitudinal Study in Taiwan. <i>American Journal of Epidemiology</i> , 2014, 180, 103-110.	1.6	30
191	Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. <i>Transplant Infectious Disease</i> , 2014, 16, 1003-1006.	0.7	12
192	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014, 61, 67-74.	1.8	110
193	Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics. <i>Hepatology International</i> , 2014, 8, 224-232.	1.9	12
194	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. <i>Antiviral Research</i> , 2014, 105, 135-142.	1.9	16
195	Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep/Cobas TaqMan HBV assay for HBV DNA detection and quantification. <i>Journal of Clinical Virology</i> , 2014, 60, 206-214.	1.6	34
196	High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. <i>Journal of Hepatology</i> , 2014, 60, 253-259.	1.8	58
197	Impact of Chronic Hepatitis B and Hepatitis C on Adverse Hepatic Fibrosis in Hepatocellular Carcinoma Related to Betel Quid Chewing. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 637-642.	0.5	17
198	Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver. <i>BMC Medical Genetics</i> , 2013, 14, 54.	2.1	15

#	ARTICLE	IF	CITATIONS
199	Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. <i>Hepatology International</i> , 2013, 7, 162-170.	1.9	4
200	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. <i>Hepatology International</i> , 2013, 7, 180-187.	1.9	2
201	Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. <i>Indian Journal of Gastroenterology</i> , 2013, 32, 253-257.	0.7	23
202	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	3.6	66
203	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013, 56, 293-298.	1.6	20
204	Host factors determining the efficacy of hepatitis C treatment. <i>Journal of Gastroenterology</i> , 2013, 48, 22-30.	2.3	28
205	Clinical utility of host genetic $\epsilon$ 28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1515-1520.	1.4	14
206	Outcome assessment in acute pancreatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 469-477.	0.8	10
207	Association between gallbladder stones and chronic hepatitis C: Ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 430-435.	0.8	8
208	Glucose abnormalities in hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 61-68.	0.8	25
209	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	3.6	47
210	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	1.3	17
211	Pegylated Interferon- $\alpha$ 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	2.0	91
212	Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients. <i>PLoS ONE</i> , 2013, 8, e58882.	1.1	13
213	Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. <i>Translational Research</i> , 2012, 159, 58-59.	2.2	14
214	The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. <i>Liver International</i> , 2012, 32, 962-969.	1.9	20
215	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2012, 56, 34-40.	1.8	77
216	Tarry Stool in a Man With Acute Pancreatitis. <i>Gastroenterology</i> , 2012, 143, e5-e6.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2012, 28, 86-93.	0.8	11
218	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. <i>Hepatology International</i> , 2012, 6, 613-619.	1.9	4
219	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.	1.9	152
220	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. <i>Antiviral Research</i> , 2012, 93, 239-244.	1.9	44
221	Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. <i>PLoS ONE</i> , 2012, 7, e52048.	1.1	23
222	Performance characteristics of a combined hepatitis C virus core antigen and anti- $\alpha$ hepatitis C virus antibody test in different patient groups. <i>Kaohsiung Journal of Medical Sciences</i> , 2011, 27, 258-263.	0.8	16
223	The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies $\hat{\alpha}$ A multicenter prospective trial. <i>Journal of Hepatology</i> , 2011, 54, 219-226.	1.8	24
224	Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection. <i>Hepatology Research</i> , 2011, 41, 430-436.	1.8	13
225	Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 530-535.	1.4	13
226	The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. <i>Liver International</i> , 2011, 31, 1326-1331.	1.9	65
227	Pegylated interferon plus ribavirin therapy improves pancreatic $\beta$ cell function in chronic hepatitis C patients. <i>Liver International</i> , 2011, 31, 1155-1162.	1.9	15
228	Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. <i>Hepatology</i> , 2011, 53, 7-13.	3.6	168
229	Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. <i>Hepatology</i> , 2011, 53, 367-368.	3.6	16
230	Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. <i>Hepatology</i> , 2011, 53, 1399-1399.	3.6	7
231	Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story. <i>Hepatology</i> , 2011, 53, 1774-1775.	3.6	1
232	Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals. <i>Hepatology</i> , 2011, 54, 1108-1109.	3.6	2
233	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. <i>PLoS ONE</i> , 2011, 6, e20752.	1.1	18
234	Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. <i>Hepatology International</i> , 2010, 4, 601-607.	1.9	10

#	ARTICLE	IF	CITATIONS
235	Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. <i>Hepatology International</i> , 2010, 4, 621-627.	1.9	23
236	Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. <i>Hepatology International</i> , 2010, 4, 732-740.	1.9	16
237	Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. <i>Antiviral Research</i> , 2010, 85, 396-402.	1.9	18
238	Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: The important role of initial ribavirin doses. <i>Hepatology</i> , 2010, 51, 1861-1862.	3.6	2
239	Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 758-765.	1.4	26
240	Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2010, 201, 751-759.	1.9	359
241	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	1.9	46
242	Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection. <i>Gut</i> , 2010, 59, 418-418.	6.1	2
243	Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan. <i>Journal of Hepatology</i> , 2010, 52, 160-166.	1.8	47
244	Intestinal Parasitic Infection Detected by Stool Examination in Foreign Laborers in Kaohsiung. <i>Kaohsiung Journal of Medical Sciences</i> , 2010, 26, 136-143.	0.8	14
245	Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study. <i>Kaohsiung Journal of Medical Sciences</i> , 2010, 26, 461-469.	0.8	100
246	Unveiling Glucose Abnormalities in Patients With Chronic Hepatitis C Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 1051-1051.	0.2	0
247	The Substantial Role of Initial Ribavirin Dose on the Response to Peginterferon ±/Ribavirin Therapy in Patients With Genotype 1b Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 2358-2359.	0.2	0
248	Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL. <i>Hepatology</i> , 2009, 49, 704-705.	3.6	5
249	Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: Some concerns. <i>Hepatology</i> , 2009, 49, 2125-2125.	3.6	1
250	A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration. <i>Hepatology</i> , 2009, 49, 1395-1396.	3.6	4
251	Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1000-1010.	1.9	19
252	Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. <i>International Journal of Obesity</i> , 2009, 33, 1309-1317.	1.6	27

#	ARTICLE	IF	CITATIONS
253	Treatment of chronic hepatitis C in Asia: When East meets West. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 336-345.	1.4	227
254	HBV infection in indigenous children, 20 years after immunization in Taiwan: A community-based study. <i>Preventive Medicine</i> , 2009, 48, 397-400.	1.6	12
255	What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? Beyond the applause for higher sensitivity. <i>Journal of Hepatology</i> , 2009, 50, 212.	1.8	0
256	Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 50, 471-478.	1.8	20
257	Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2009, 50, 712-718.	1.8	144
258	Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 614-618.	1.5	15
259	Hepatitis C Virus Infection And Metabolic Syndrome – A Community-Based Study in an Endemic Area of Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2009, 25, 299-305.	0.8	32
260	Comparison of Clinical Application of the Abbott HBV PCR Kit and the Versant HBV DNA 3.0 Test to Measure Serum Hepatitis B Virus DNA in Taiwanese Patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2009, 25, 413-422.	0.8	9
261	Hepatocellular Carcinoma Associated With Liver Abscess. <i>Kaohsiung Journal of Medical Sciences</i> , 2009, 25, 537-543.	0.8	12
262	Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues. <i>Hepatology</i> , 2008, 47, 1792-1793.	3.6	2
263	Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2. <i>Hepatology</i> , 2008, 48, 342-342.	3.6	2
264	Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. <i>Hepatology</i> , 2008, 47, 1884-1893.	3.6	299
265	Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure. <i>Hepatology</i> , 2008, 48, 692-693.	3.6	0
266	Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: The role of weight-based ribavirin exposure. <i>Hepatology</i> , 2008, 48, 1019-1020.	3.6	11
267	Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008, 102, 929-934.	0.7	16
268	Hepatitis C virus infection among children in aboriginal areas in Taiwan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008, 102, 935-938.	0.7	9
269	Association between transforming growth factor-beta 1 polymorphism and virologic characteristics of chronic hepatitis C. <i>Translational Research</i> , 2008, 152, 151-156.	2.2	8
270	Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study. <i>Journal of Hepatology</i> , 2008, 49, 9-16.	1.8	142



#	ARTICLE	IF	CITATIONS
271	Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 475-80.	1.4	4
272	Abnormal Liver Function Test Predicts Type 2 Diabetes: a Community-Based Prospective Study: Response to Cho et al.. <i>Diabetes Care</i> , 2008, 31, e53-e53.	4.3	5
273	Revisit of Oral Glucose Tolerance Test: A Must for Diagnosis of Type 2 Diabetes in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2008, 103, 487-488.	0.2	2
274	Reappraisal of the Characteristics of Glucose Abnormalities in Patients With Chronic Hepatitis C Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 1933-1940.	0.2	51
275	High Serum Uric Acid as a Novel Risk Factor for Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, e67-e67.	4.3	4
276	Prevention of Donor to Recipient Transmission of HCV in Stem Cell Transplantation: Some Issues. <i>American Journal of Gastroenterology</i> , 2007, 102, 2350-2351.	0.2	0
277	Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication. <i>American Journal of Gastroenterology</i> , 2007, 102, 1237-1243.	0.2	119
278	Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. <i>Journal of Clinical Pathology</i> , 2007, 61, 333-337.	1.0	42
279	The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. <i>Gut</i> , 2007, 56, 736-737.	6.1	61
280	Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis C. <i>Oncology</i> , 2007, 72, 16-23.	0.9	32
281	The role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and C. <i>Gut</i> , 2007, 56, 737-738.	6.1	7
282	A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. <i>Gut</i> , 2007, 56, 553-559.	6.1	257
283	Qualitative Application of COBAS AMPLICOR HCV Test Version 2.0 Assays in Patients with Chronic Hepatitis C Virus Infection and Comparison of Clinical Performance with Version 1.0. <i>Kaohsiung Journal of Medical Sciences</i> , 2007, 23, 332-338.	0.8	6
284	Tumor Necrosis Factor- $\alpha$ 308.2 Polymorphism Is Associated with Advanced Hepatic Fibrosis and Higher Risk for Hepatocellular Carcinoma. <i>Neoplasia</i> , 2007, 9, 987-992.	2.3	76
285	Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 515-517.	1.4	48
286	Significant correlations between severe fatty liver and risk factors for metabolic syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 2118-2123.	1.4	121
287	Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386-patient study from Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1029-1037.	1.9	61
288	Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation. <i>Liver International</i> , 2007, 27, 1364-1370.	1.9	8

#	ARTICLE	IF	CITATIONS
289	Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. <i>Antiviral Research</i> , 2007, 75, 146-151.	1.9	20
290	Links between triglyceride levels, hepatitis C virus infection and diabetes. <i>Gut</i> , 2007, 56, 1167-8.	6.1	5
291	Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. <i>Japanese Journal of Infectious Diseases</i> , 2007, 60, 377-81.	0.5	20
292	Etiology, Severity and Recurrence of Acute Pancreatitis in Southern Taiwan. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 550-555.	0.8	33
293	Early mortality in taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. <i>Clinical Therapeutics</i> , 2006, 28, 2081-2092.	1.1	24
294	Diagnosis of Icteric-Type Hepatocellular Carcinoma by Fine Needle Aspiration. <i>Acta Cytologica</i> , 2006, 50, 531-533.	0.7	3
295	Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 398-405.	1.4	9
296	A randomized trial of 24- vs. 48-week courses of PEG interferon $\alpha$ -2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. <i>Liver International</i> , 2006, 26, 73-81.	1.9	43
297	A 24-week course of high-dose interferon- $\alpha$ plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. <i>Liver International</i> , 2006, 26, 1187-1195.	1.9	8
298	Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. <i>European Journal of Clinical Investigation</i> , 2006, 36, 176-180.	1.7	27
299	Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?. <i>Journal of Internal Medicine</i> , 2006, 260, 255-262.	2.7	85
300	The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. <i>Journal of Viral Hepatitis</i> , 2006, 13, 396-401.	1.0	31
301	Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2006, 13, 770-774.	1.0	25
302	Selenium, Iron, Copper, and Zinc Levels and Copper-to-Zinc Ratios in Serum of Patients at Different Stages of Viral Hepatic Diseases. <i>Biological Trace Element Research</i> , 2006, 109, 015-024.	1.9	82
303	Primary Hepatocellular Carcinoma Detected Long After Tumor Markers and Lymph Node Metastases—Beyond Our Vision?. <i>Digestive Diseases and Sciences</i> , 2006, 51, 610-615.	1.1	1
304	A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. <i>Hepatology</i> , 2006, 44, 1086-1097.	3.6	107
305	Tumor Necrosis Factor $\alpha$ -1 Promoter Polymorphism at Position -308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 193, 98-101.	1.9	63
306	Treatment of Chronic Hepatitis C in Southern Taiwan. <i>Intervirology</i> , 2006, 49, 99-106.	1.2	63

#	ARTICLE	IF	CITATIONS
307	SEN and Hepatitis Virus Infections in Nontransfused Children and Pediatric Thalassemia Patients with Multiple Transfusions in Taiwan. <i>Digestion</i> , 2006, 74, 208-214.	1.2	5
308	Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. <i>Antiviral Therapy</i> , 2006, 11, 1015-9.	0.6	6
309	Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon- $\alpha$ plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , 2006, 11, 1015-1020.	0.6	29
310	SEN virus infection among patients on maintenance hemodialysis in southern Taiwan. <i>Journal of Infection</i> , 2005, 51, 110-115.	1.7	8
311	Safety of fine-needle aspiration in patients with small hepatocellular carcinoma. <i>Hepatology Research</i> , 2005, 31, 31-35.	1.8	10
312	Polymorphisms in the interferon- $\beta$ gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon- $\alpha$ and ribavirin. <i>Antiviral Research</i> , 2005, 67, 93-97.	1.9	21
313	Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 68-75.	0.6	47
314	Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon- $\alpha$ and ribavirin. <i>World Journal of Gastroenterology</i> , 2005, 11, 4241.	1.4	6
315	Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. <i>Liver International</i> , 2004, 24, 595-602.	1.9	14
316	CT evaluation of gastrointestinal tract perforation. <i>Clinical Imaging</i> , 2004, 28, 329-333.	0.8	70
317	A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. <i>Antiviral Research</i> , 2004, 63, 25-32.	1.9	18
318	Prevalence and Clinical Significance of SEN Virus Infection Among Volunteer Blood Donors in Southern Taiwan. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1181-1185.	1.1	7
319	Imaging of Transmural Migration of A Retained Surgical Sponge: A Case Report. <i>Kaohsiung Journal of Medical Sciences</i> , 2004, 20, 567-571.	0.8	13
320	Tumor necrosis factor $\alpha$ promoter polymorphisms at position $\sim$ 308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. <i>Antiviral Research</i> , 2003, 59, 35-40.	1.9	19
321	Serum Insulin-Like Growth Factor-II and $\alpha$ -Fetoprotein as Tumor Markers of Hepatocellular Carcinoma. <i>Tumor Biology</i> , 2003, 24, 291-298.	0.8	36
322	The prevalence of TT virus and GB virus C/hepatitis G virus infection in individuals with raised liver enzymes but without HBV or HCV infection in Taiwan. <i>Epidemiology and Infection</i> , 2002, 129, 307-313.	1.0	4
323	Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. <i>Journal of Hepatology</i> , 2002, 36, 236.	1.8	0
324	Anti-HCV-positive teenagers in HCV-endemic townships in Taiwan. <i>Journal of Hepatology</i> , 2002, 36, 238-239.	1.8	1

#	ARTICLE	IF	CITATIONS
325	The response of hepatitis C virus and TT virus to high dose and long duration interferon-alpha therapy in naïve chronic hepatitis C patients. <i>Antiviral Research</i> , 2002, 53, 9-18.	1.9	11
326	Incidence and clinical outcome of icteric type hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 190-195.	1.4	71
327	Clinical characteristics and distribution of genotypes of TT virus infection in a hepatitis C virus-hyperendemic township of a hepatitis B virus-endemic country (Taiwan). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 1192-1197.	1.4	4
328	The molecular epidemiology and clinical significance of TT virus (TTV) infection in healthy blood donors from Southern Taiwan. <i>Transfusion and Apheresis Science</i> , 2001, 24, 9-15.	0.5	8
329	Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. <i>Epidemiology and Infection</i> , 2001, 127, 485-492.	1.0	36
330	Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 636-640.	1.4	56
331	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. <i>Journal of Medical Virology</i> , 2001, 65, 58-65.	2.5	97
332	The Serological and Molecular Epidemiology of GB Virus C/Hepatitis G Virus Infection in a Hepatitis C and B Endemic Area. <i>Journal of Infection</i> , 2001, 42, 61-66.	1.7	13
333	GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon- $\alpha$ therapy. <i>Antiviral Research</i> , 2001, 52, 241-249.	1.9	20
334	Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 417-421.	1.4	22
335	Serotyping and genotyping of hepatitis C virus in Taiwanese patients with type C chronic liver disease and uraemic patients on maintenance haemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 792-797.	1.4	7
336	Status and natural course of GB virus C/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1404-1410.	1.4	15
337	Clinical Evaluation of the Automated COBAS AMPLICOR HCV MONITOR Test Version 2.0 for Quantifying Serum Hepatitis C Virus RNA and Comparison to the Quantiplex HCV Version 2.0 Test. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2933-2939.	1.8	46
338	Incidence and Associated Factors of Neutralizing Anti-Interferon Antibodies among Chronic Hepatitis C Patients Treated with Interferon in Taiwan. <i>Scandinavian Journal of Gastroenterology</i> , 2000, 35, 1288-1293.	0.6	17
339	Percutaneous ethanol injection of the supplying artery to hepatocellular carcinoma that is not amenable to conventional treatment.. <i>British Journal of Radiology</i> , 2000, 73, 833-839.	1.0	4
340	Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. <i>European Journal of Endocrinology</i> , 2000, 142, 431-437.	1.9	72
341	A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1999, 93, 253-254.	0.7	44
342	Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area. <i>Pediatric Infectious Disease Journal</i> , 1998, 17, 142-145.	1.1	33

#	ARTICLE	IF	CITATIONS
343	Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 547-550.	1.4	47
344	Hepatic focal nodular hyperplasia: findings on color Doppler ultrasound. <i>Abdominal Imaging</i> , 1997, 22, 178-181.	2.0	52